This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Bmp 2
FDA-approved recombinant osteogenic protein delivered on a collagen sponge during surgery (Infuse).
Aliases (4)
Overview
What is Bmp 2?
Bone Morphogenetic Protein-2 (BMP-2, marketed as Infuse / dibotermin alfa) is a recombinant human growth factor in the TGF-beta superfamily. FDA-approved for spinal fusion, open tibial fractures, and oral/maxillofacial defects, delivered locally on a collagen sponge.
Key Benefits
Powerful osteoinductive agent — induces de novo bone formation at the surgical site, replacing the need for autologous bone graft in select indications, accelerates spinal fusion and fracture healing.
Mechanism of Action
Binds BMP receptors (BMPR-1A/1B/2), activating SMAD1/5/8 signaling to drive mesenchymal stem cell differentiation into osteoblasts. Triggers cascading expression of osteogenic transcription factors (Runx2, Osterix) and bone-matrix proteins.
Pharmacokinetics
What to Expect
- Week 1Tolerability and dose-response.
- Week 2-4Early effect window.
- Week 4-8Peak benefit assessment.
- Week 8+Cycle decision point.
Side Effects & Safety
- Common (>10% in surgical context): Site swelling, transient inflammation, bone overgrowth at margins
- Less common (1-10%): Radiculitis, seroma, retrograde ejaculation (anterior approaches), wound complications
- Rare-serious (<1% but worth knowing):
- Cancer signal: Carragee 2011 meta-analysis flagged increased malignancy at 24 months with high-dose Amplify (40 mg) — FDA never approved Amplify partly for this reason. Lower-dose Infuse signal is contested but non-zero.
- Cervical airway compromise — FDA Public Health Notification 2008 after deaths from soft-tissue swelling
- Heterotopic ossification in spinal canal causing neurologic deficit
- Osteolysis/resorption preceding bone deposition (transient)
- Specific watch periods: Post-op week 1-2 for swelling; year 1-2 for cancer surveillance in high-dose recipients
References
Carragee EJ, et al. (2011) — A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine Journal
PMID 21701760, the watershed paper raising cancer + complication concerns
View StudyGovender S, et al. (2002) — Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures (BESTT trial). J Bone Joint Surg Am
PMID 12473698, the original tibial-fracture pivotal trial
View StudySimmonds MC, et al. (2013) — Safety and effectiveness of recombinant human bone morphogenetic protein-2 for spinal fusion: a meta-analysis of individual-participant data. Annals of Internal Medicine
PMID 23778906, YODA reanalysis
View StudyFu R, et al. (2013) — Effectiveness and harms of recombinant human bone morphogenetic protein-2 in spine fusion: a systematic review and meta-analysis. Annals of Internal Medicine
PMID 23778905, companion YODA paper
View StudyTannoury CA, An HS (2014) — Complications with the use of bone morphogenetic protein 2 in spine surgery. Spine Journal
PMID 24216397, complication review
View StudyHow was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.